Milwaukee-based The Dohmen Company has appointed Eric Floyd as chief science officer of Dohmen Life Science Services. In the newly created role, Floyd will lead Dohmen’s growing regulatory consulting practice, as well as a portfolio of pre-commercial and post-approval outsourced services in quality, regulatory, pharmacovigilence, REMS, medical affairs and medical communications.
Floyd, who holds an MBA and Ph.D. in neurophysiology, most recently served as vice president of U.S. regulatory affairs and clinical quality assurance and vice president of global regulatory affairs at Lundbeck Inc.
“This area of expertise is of particular strategic focus for Dohmen,” said Cynthia LaConte, chief executive officer of Dohmen. “As precision medicine begins to take root, with continued interest and investment in the rare disease space, we can see the ripple effect in all aspects of development and commercialization. We’ve invested heavily, on behalf of our life science clients, in best practice tools, technology and talent in support of this sea of change. Serving small markets requires a different strategic approach to the marketplace, starting with clinical trial design and continuing through the product’s lifecycle.
“Eric’s experience with global regulators in pharma, bio and in particular within the orphan drug space will help our clients navigate new paradigms for development, clinical trial and ongoing safety requirements.”
Floyd brings decades of experience leading global regulatory affairs and quality assurance divisions within Novartis, Cephalon Inc., Hospira Inc. and Lundbeck. Floyd has also worked in global regulatory affairs at Aventis Pharmaceuticals, Bristol-Myers Squibb Co. and Merck Research Laboratories.
“The opportunity that lies ahead for DLSS is tremendous,” Floyd said. “Dohmen has built a strong portfolio of capability in response to changing industry dynamics. They’re clearly on the leading edge of that change with services that span a product’s journey from clinical trial to patient care. I’ll be focused on advancing the compliance business unit with a diverse array of services that range from pre-commercial consulting to in market call center support.
“I’m looking forward to leveraging the reputational excellence of a brand that’s been in market for over 157 years and providing the innovation that our customers expect from us. It’s a pleasure to find an organization where I can use my knowledge and experience to advance the DLSS mission of reducing the burden of disease by connecting life science innovators with the patients they serve.”
